DBV Technologies Submits BLA to FDA for VIASKIN® Peanut Patch in Children 4–7

What Happened DBV Technologies S.A. announced (via a press release dated September 29, 2026) that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for its VIASKIN® Peanut Patch intended for children aged 4–7 years. The company filed a Form 8-K on September 30, 2026 to report this event and attached the press release as Exhibit 99.1.

Key Details

• Company: DBV Technologies S.A.
• Event: Submission of a Biologics License Application (BLA) to the U.S. FDA.
• Product: VIASKIN® Peanut Patch for children aged 4–7 years.
• Disclosure: Press release dated Sept. 29, 2026 attached to the 8-K (Exhibit 99.1); 8-K filed Sept. 30, 2026.

Why It Matters This BLA submission is a major regulatory milestone that initiates the FDA review process for DBV’s lead product in the younger-child population. For investors, it signals progress toward potential U.S. regulatory approval and future commercialization opportunities for the VIASKIN® Peanut Patch, which could materially affect the company’s clinical and commercial outlook depending on the FDA’s review and any subsequent decisions. Investors should monitor FDA communications, review timelines, and further company updates.